Category: 29735-85-1

Nakanishi, Teruo; Saeki, Toru published an article in 1970, the title of the article was Inhibitory action of benzofuran compounds on 5′-AMP deaminase and adenosine deaminase.Quality Control of 5-Hydroxybenzofuran-3-carboxylic acid And the article contains the following content:

The inhibitory action of benzofuran derivatives on 5′-AMP deaminase (I) and adenosine deaminase (II) was investigated by using a number of synthetic compounds Introduction of carboxyl or hydroxyl groups increased the inhibitory action on I, but no pronounced effect of the substituent was observed on II. No common feature in structure seems to exist for the inhibition of these 2 deaminases. The experimental process involved the reaction of 5-Hydroxybenzofuran-3-carboxylic acid(cas: 29735-85-1).Quality Control of 5-Hydroxybenzofuran-3-carboxylic acid

The Article related to benzofurans inhibition deaminases, deaminases inhibition benzofurans, inhibition deaminases benzofurans, amp deaminase inhibition benzofurans, and other aspects.Quality Control of 5-Hydroxybenzofuran-3-carboxylic acid

Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem

On December 16, 2021, Andrews, Mark; Soerensen, Morten Dahl; Larsen, Mogens; Devaux, Nicolas; Barros Ribeiro da Silva, Vicinius; Perron, Quentin; Liang, Xifu; Seitzberg, Jimmi Gerner published a patent.Recommanded Product: 29735-85-1 The title of the patent was N-Heteroaryl and N-aryl amidoamides as small molecule modulators of IL-17 and their preparation. And the patent contained the following:

The invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments. Compounds of formula I wherein X, Y, Z and V are independently N, CH and CR4; R1 is (un)substituted C1-4 alkyl, (un)substituted C3-7 cycloalkyl, C1-6 alkoxy, (un)substituted Ph, etc.; R2 is (un)substituted 5- to 6-membered heteroaryl; R3 is CHR5R6, (un)substituted C3-10 cycloalkyl, (un)substituted tetrahydronaphthyl, etc.; R4 is (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, OH, NH2 and halo; R5 and R6 are independently H, (un)substituted Ph, (un)substituted C1-6 alkyl, (un)substituted C3-7 cycloalkyl, etc.; and pharmaceutically acceptable salts, hydrates and solvates thereof, are claimed. Example compound II was prepared by deprotection of N-[(1S)-1-(dicyclopropylmethyl)-2-[[5-[3,5-dimethyl-1-(2-trimethylsilylethoxymethyl)pyrazol-4-yl]-6-fluoro-2-pyridyl]amino]-2-oxo-ethyl]-2-isopropylpyrazole-3-carboxamide. The invention compounds were evaluated for their IL-17 modulatory activity. From the assay, it was determined that compound II exhibited EC50 value of 15 nM. The experimental process involved the reaction of 5-Hydroxybenzofuran-3-carboxylic acid(cas: 29735-85-1).Recommanded Product: 29735-85-1

The Article related to heteroaryl aryl amidoamide preparation il17 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Recommanded Product: 29735-85-1

Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem

On February 3, 2005, Cheng, Jie Fei; Nguyen, Bao Ngoc; Liu, Xuewei; Lopaschuk, Gary D.; Dyck, Jason R. published a patent.Product Details of 29735-85-1 The title of the patent was Preparation of heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors. And the patent contained the following:

The present invention provides methods for the use of compounds I [X1, X2, X3 = O, N, NH, NR5, S, C; R1, R2 = H, halogen, substituted C1-6-alkyl, substituted C1-6-alkenyl, substituted C1-6-alkynyl, alkoxy, (un)substituted Ph, aryl, (un)substituted heteroaryl, NHCONR5R6, COR5, CONR5R6, S(O)nR5, SO2NR5R6; R3, R4 = H, Br, Cl, F, I, OH, OMe, CO2H, CO2R5, CONR5R6, S(O)nR5, SO2NR5R6, substituted C1-6-alkyl, C1-6-alkoxy, (un)substituted Ph, aryl, heteroaryl; R5, R6 = H, (un)substituted C1-6-alkyl, (un)substituted Ph, aryl, heteroaryl], its enantiomers, diastereomers, tautomers, or physiol. acceptable salts or prodrugs, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. Thus, benzofuran I [X1 = CC(:O)NHC6H3(OMe)2-3,4, X2 = CH, X3 = O, R3 = 4-Br, R4 = 6-Br] was prepared from 5-methoxybenzofuran-2-carboxylic acid via regioselective bromination at C(3), decarboxylation, debromination-carboxylation at C(3), O-demethylation, regioselective dibromination and amidation with 3,4-dimethoxyaniline. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. The inhibitory activity of I vs. malonyl-CoA decarboxylase was determined [Ki = 31.6 – 4750.2 μM]. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity. The experimental process involved the reaction of 5-Hydroxybenzofuran-3-carboxylic acid(cas: 29735-85-1).Product Details of 29735-85-1

The Article related to heterocyclic compound preparation malonyl coa decarboxylase inhibitor, cardiovascular disease prophylaxis management treatment heterocyclic compound, diabetes prophylaxis management treatment heterocyclic compound, cancer prophylaxis management treatment heterocyclic compound, obesity prophylaxis management treatment heterocyclic compound and other aspects.Product Details of 29735-85-1

Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem